Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proton Pump Inhibitors Use in Patients With Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02624544
Recruitment Status : Unknown
Verified November 2015 by EMS.
Recruitment status was:  Not yet recruiting
First Posted : December 8, 2015
Last Update Posted : December 8, 2015
Sponsor:
Information provided by (Responsible Party):
EMS

Brief Summary:
Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: esomeprazole Drug: desonide Phase 4

Detailed Description:

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

The study will assess the evolution of skin lesions in psoriasis patients using PPIs


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Proton Pump Inhibitors Use in Patients With Psoriasis
Study Start Date : January 2016
Estimated Primary Completion Date : January 2016
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Group A
Proton Pump Inhibitor esomeprazole 40 mg twice a day
Drug: esomeprazole
esomex 40 mg twice daily
Other Name: esomex

Active Comparator: Group B
desonide
Drug: desonide
topical corticosteroid desonid 0,1% b.i.d
Other Name: corticosteroid




Primary Outcome Measures :
  1. Efficacy - Change from baseline in skin lesions at 5 months [ Time Frame: Baseline - 5 months ]
    Number of Participants With Treatment-Related Clinical Improvement of lesions Change From Baseline in skin lesions at 5 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnostic of Psoriasis

Exclusion Criteria:

  • Pregnancy

Publications of Results:
Layout table for additonal information
Responsible Party: EMS
ClinicalTrials.gov Identifier: NCT02624544     History of Changes
Other Study ID Numbers: EMS
First Posted: December 8, 2015    Key Record Dates
Last Update Posted: December 8, 2015
Last Verified: November 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Esomeprazole
Proton Pump Inhibitors
Desonide
Anti-Ulcer Agents
Gastrointestinal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents